XNASVYNE
Market cap57mUSD
Jan 08, Last price
3.92USD
1D
-8.41%
1Q
113.04%
IPO
-97.96%
Name
Vyne Therapeutics Inc
Chart & Performance
P/E
—
P/S
136.38
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
102.60%
Rev. gr., 5y
-47.51%
Revenues
424k
-11.11%
Net income
-28m
L-16.18%
CFO
-25m
L-13.22%
Earnings
Feb 26, 2025
Profile
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 424 -11.11% | 477 -96.77% | |||||||
Cost of revenue | 29,682 | 34,772 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (29,258) | (34,295) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 13 | ||||||||
Tax Rate | |||||||||
NOPAT | (29,258) | (34,308) | |||||||
Net income | (28,452) -16.18% | (33,945) -53.71% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 82,461 | 1,470 | |||||||
BB yield | -344.50% | -307.60% | |||||||
| Debt | |||||||||
Debt current | 230 | ||||||||
Long-term debt | 313 | (698) | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,313 | 560 | |||||||
Net debt | (92,710) | (31,606) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (25,341) | (29,200) | |||||||
CAPEX | |||||||||
Cash from investing activities | (57,354) | 15,667 | |||||||
Cash from financing activities | 82,394 | 1,653 | |||||||
FCF | (26,064) | (37,355) | |||||||
| Balance | |||||||||
Cash | 93,253 | 30,908 | |||||||
Long term investments | |||||||||
Excess cash | 93,232 | 30,884 | |||||||
Stockholders' equity | (691,309) | (661,054) | |||||||
Invested Capital | 781,686 | 692,467 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 10,273 | 3,186 | |||||||
Price | 2.33 1,453.33% | 0.15 -85.29% | |||||||
Market cap | 23,936 4,908.64% | 478 -83.61% | |||||||
EV | (68,774) | (30,917) | |||||||
EBITDA | (29,258) | (34,223) | |||||||
EV/EBITDA | 2.35 | 0.90 | |||||||
Interest | 10,807 | ||||||||
Interest/NOPBT | |||||||||